This article is part of the supplement: The role of IFN alpha in autoimmune disease
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
Arthritis Research & Therapy 2010, 12(Suppl 1):S6 doi:10.1186/ar2887
